Drug Profile


Alternative Names: Crinobulin; Crolibulin; EP2407; EPC 2407; MX-2407; MX116407

Latest Information Update: 23 Sep 2015

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer Immune Pharmaceuticals Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Benzopyrans; Nitriles; Small molecules
  • Mechanism of Action Apoptosis stimulants; Microtubule protein inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Lymphoma

Most Recent Events

  • 23 Sep 2015 Crolibulin is still in phase I/II trials for Solid tumours (Combination therapy) in the USA
  • 26 Aug 2013 EpiCept Corporation merged with Immune Pharmaceuticals Ltd to form Immune Pharmaceuticals Inc
  • 03 Jun 2013 Interim adverse events data from a phase I/II trial in Solid tumours presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO-2013)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top